Global Sickle Cell Disease Treatment Market (2019-2023) to Grow at a CAGR of More Than 11% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Sickle Cell Disease Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The sickle cell disease treatment market will register a CAGR of over 11% by 2023.

Strong pipeline of drugs to drive market growth

The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the late stages of clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies. Thus, helping the vendors with quick development of these drugs.

High prevalence of sickle cell disease

The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, according to the CDC. in 2017, sickle cell diseases affected approximately 100,000 Americans. While it is rather rare in Hispanic-Americans and Asian-Americans, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people.

Lack of approved therapies

Despite blood transfusion being heavily used to treat sickle cell diseases, the market faces a major challenge from the lack of approved therapies. Currently, the market has only three approved therapies for sickle cell diseases, and six molecules are in Phase Ill of clinical trials.

Key Players

• Addmedica
• Bristol-Myers Squibb
• Emmaus Medical
• Novartis
• Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY INDICATION

• Comparison by indication
• Sickle cell anemia - Market size and forecast 2018-2023
• Sickle beta thalassemia - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by indication

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Addmedica
• Bristol-Myers Squibb
• Emmaus Medical
• Novartis
• Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/np9xwr/global_sickle?w=4